Jump to any asset
849 assets, updated daily
As of September 27, 2026, IDEXX Laboratories, Inc. (IDXX) trades at $519.26. CleaRank Financial AI rates it Hold with a fair value of $519.26, in line with the current price. Wall Street's consensus target is $700.00 across 14 analysts. RSI at 40 is in neutral territory, and the price is below its 50-day average of $546.74.
IDEXX Laboratories, Inc. (IDXX)
IDEXX Laboratories, Inc. NASDAQ
$519.26
5.870 (1.14%)
At close: Sep 25, 4:00 PM EDT
AI Analyst Consensus
59 / 100
IDEXX Laboratories, Inc. (IDXX) is currently trading at $519.26, below its 50-day and 200-day moving averages ($546.74 and $592.41), signaling a bearish technical trend. The company operates within the Healthcare sector, specifically in Diagnostics & Research, and has demonstrated strong historical growth and profitability. Despite a solid profit margin of 25.03% and a return on equity of 74.21%, the stock's current price action and substantial insider selling raise concerns. Analysts maintain a 'Hold' consensus with a median price target of $700, implying a potential 34.8% upside, but the significant net selling activity from insiders warrants caution.
IDXX Price Analysis
Market Metrics
Open
$510.94
Day Range
$507.01 to $520.16
Prev Close
$513.39
Volume
331.1K
52-Week Range
$500.61 to $769.98
Market Cap
$40.96B
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
Valuation is broadly in line with sector peers (14% difference), suggesting fair market pricing relative to industry standards.
IDXX Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
Analysis: In the last 4 quarters, IDXX beat estimates 4 times. However, the stock fell 3 times the next day. This suggests positive news is often "priced in" or investors are selling the news.
IDXX Analysis
Company's Health
4/5
12-Month Analyst Target
+34.81% Upside
Median of 14 analysts (12-month)
$700.00
AI Technical Analysis
IDEXX Laboratories is trading below its 50-day SMA of $546.74 and its 200-day SMA of $592.41, indicating a bearish trend. The RSI is at 39.5, reflecting bearish momentum, and the MACD is at -9.33, further supporting a negative technical outlook. The stock is also below its 20-day EMA of $523.68. The current price action suggests downward pressure. Volume was 34.2% below average on the latest trading day, indicating reduced investor interest. The chart structure points towards continued weakness unless a significant bullish catalyst emerges.
ProTips
- Monitor insider transactions closely; the current heavy net selling by insiders warrants significant attention and could signal management's short-term concerns.
- Pay attention to the 50-day and 200-day moving averages as key indicators of trend direction; a sustained break above these levels would be a bullish signal.
- Given the premium valuation, any signs of slowing revenue growth or increased competition could negatively impact the stock price.
Key Catalysts
Bearish
Heavy Insider Selling Pressure
Insiders have sold over $75.1 million worth of IDXX stock with no reported purchases, indicating a strong net selling signal that could weigh on future price performance.
Source: Insider TransactionsBearish
Trading Below Key Moving Averages
The stock is currently positioned below its 50-day SMA ($546.74) and 200-day SMA ($592.41), suggesting a bearish technical trend and potential for further downside.
Source: Technical AnalysisBullish
Positive Analyst Price Targets
The median analyst price target for IDXX is $700, suggesting a potential upside of 34.8% from the current trading price, indicating analyst confidence in future appreciation.
Source: Wall Street AnalystsBullish
Strong Profitability and ROE
IDEXX Laboratories consistently delivers strong profit margins (25.03%) and a high return on equity (74.21%), outperforming sector averages and demonstrating operational efficiency.
Source: Company FundamentalsMarket Outlook
The base case for IDEXX Laboratories over the next 6-12 months anticipates a potential recovery towards the median analyst target price of $700, representing a 34.8% upside from the current price. This outlook is supported by the company's strong historical growth, strong profit margins, and positive forward-looking revenue estimates, with current year revenue growth projected at 10.00% and next year at 9.00%. However, the thesis could be challenged by continued insider selling and a failure to break above key technical resistance levels. Downside risks include a potential valuation reset if growth slows or competitive pressures intensify, which could lead to a retest of lower support levels. Any positive catalyst, such as a significant new product launch or a shift in insider sentiment, could accelerate upside potential.
Key Statistics
| Market Cap | 40.96B |
|---|---|
| P/E Ratio | 36.44 |
| EPS (TTM) | 14.25 |
| Dividend Yield | 0.00% |
| 52 Week High | 769.98 |
| 52 Week Low | 500.61 |
IDEXX Laboratories exhibits a P/E ratio of 36.44, which is above the sector median of 31.9, suggesting a premium valuation relative to peers. Its price-to-sales ratio stands at 9.00, also higher than the sector median of 3.7. The company boasts a strong profit margin of 25.03% and an impressive return on equity of 74.21%, significantly outperforming the sector's ROE of 6.9%. While the company's profitability and efficiency metrics are strong, the current valuation appears stretched when compared to sector averages. The debt-to-equity ratio of 0.68 is within reasonable bounds, but the premium valuation combined with recent technical weakness and insider selling warrants a cautious approach.
Earnings & Growth Analysis
IDEXX Laboratories most recently reported earnings for the quarter ending June 2026, with EPS of $4.27, beating estimates of $3.93 by 8.65%. This followed a pattern of positive EPS surprises in prior quarters, though the quarter ending December 2025 showed a significant miss. Revenue growth for the current quarter is estimated at +8.00% year-over-year, with full-year revenue growth projected at +10.00%.
Key Risks
The primary risk for IDEXX Laboratories stems from significant insider selling, with over $75.1 million in sales and no reported purchases, indicating potential concerns among management. Additionally, the stock is trading below key technical indicators like the 50-day and 200-day SMAs, suggesting a bearish trend and potential for further price declines. The premium valuation relative to sector averages also presents a risk if growth expectations are not met.
Technical Indicators
| RSI (14) | 39.50 |
|---|---|
| MACD | -9.33 |
| SMA 50 | 546.74 |
| SMA 200 | 592.41 |
RSI
Bearish
SMA Cross
Bearish
Price vs SMA
Bearish
MACD
Bearish
Moving averages show a lagging Death Cross (50-day: $546.74, 200-day: $592.41), price is trading below the 50-day SMA.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.43
Moderate correlation
Nasdaq 100 (QQQ)
+0.36
Weak correlation
Bitcoin (BTC)
+0.13
Weak correlation
Gold (XAU)
+0.09
Weak correlation
Check Custom Correlation
How does any other asset move with IDXX? One year of daily closes, Pearson correlation.
Try
IDXX Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Entry Strategies pick an entry style
Conservative
$514.07
Slight discount to current
Wait for small dip
Aggressive
$519.26
At current price
Enter now if confident
Risk Management
STOP LOSS
$494.07
MAX LOSS
-3.9%
Volatility-Adjusted Stop Loss
Calculated based on RSI (39.5) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$529.49
+3% (Conservative)
+2.0% (Aggressive)
TARGET 2
$539.77
+5% (Conservative)
+4.0% (Aggressive)
TARGET 3
$555.19
+8% (Conservative)
+6.9% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
Disclaimer
This AI-generated trade plan for IDXX is for educational and informational purposes only and does not constitute financial advice. The analysis is based on historical data patterns and technical indicators which may not predict future results. Stock trading involves risk of loss. Verify all data independently and consult a qualified financial advisor. Generated on September 27, 2026.Growth of $10,000
A $10,000 investment in IDXX in September 2016 would be worth about $45,843 today, compared with about $35,782 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in IDXX today could grow to about $29,697 by 2036 in the base case, with a bull case near $111,627 and a bear case around $7,900. Projections are statistical simulations, not guarantees.
IDXX Stock Price Prediction: 2030
CleaRank's simulation projects a price near $803 for IDXX by 2030 in the base case, from $519 today (1.5x over 4 years). The downside path ends near $347. These are outcomes of a Monte Carlo simulation run on IDXX's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $381 | $579 | $880 |
| 2028 | $357 | $646 | $1,167 |
| 2029 | $349 | $720 | $1,487 |
| 2030 | $347 | $803 | $1,854 |
| 2031 | $351 | $895 | $2,282 |
| 2032 | $358 | $998 | $2,783 |
| 2033 | $367 | $1,112 | $3,368 |
| 2034 | $379 | $1,240 | $4,054 |
| 2035 | $394 | $1,383 | $4,857 |
| 2036 | $410 | $1,542 | $5,796 |
Method: 10,000 simulated price paths using IDXX's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
IDXX Insider Trading Analysis
Bought
None
No open-market buys
Sold
$75.1M
18 Transactions
Insiders
17
Active Traders
Avg Transaction
$4.2M
Large trades
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Aug 14, 2020 | MCKEON BRIAN P
Chief Financial Officer
|
Sell | 83.7K | $31.7M |
| Aug 6, 2025 | MAZELSKY JONATHAN JAY
Chief Executive Officer
|
Sell | 29.3K | $18.5M |
| Aug 17, 2020 | AYERS JONATHAN W
Director
|
Sell | 44.9K | $17.1M |
| Nov 4, 2020 | MCKEON BRIAN P
Chief Financial Officer
|
Sell | 36.2K | $17.1M |
| Feb 26, 2026 | MAZELSKY JONATHAN JAY
Chief Executive Officer
|
Sell | 23.3K | $15.3M |
| May 12, 2020 | AYERS JONATHAN W
Director
|
Sell | 50.0K | $14.8M |
| Aug 4, 2021 | TWIGGE GIOVANI
Officer
|
Sell | 20.3K | $14.2M |
| Feb 7, 2024 | MCKEON BRIAN P
Chief Financial Officer
|
Sell | 23.3K | $13.3M |
| Nov 10, 2021 | MCKEON BRIAN P
Chief Financial Officer
|
Sell | 20.0K | $12.5M |
| Nov 5, 2020 | AYERS JONATHAN W
Director
|
Sell | 26.6K | $12.5M |
Page 1 of 1
Frequently Asked Questions
What is IDEXX Laboratories' (IDXX) stock price forecast for 2030?
Based on Monte Carlo simulations, IDEXX Laboratories' stock price is projected to be $802.54 in 2030 under a base case scenario. The downside projection is $347.35, while the upside projection reaches $1854.25. These figures represent statistical simulation outcomes, not guaranteed price targets.
Is IDEXX Laboratories stock a buy right now?
IDEXX Laboratories is currently rated 'Hold' by Wall Street analysts with a consensus score of 59. While the median analyst target price suggests potential upside, the stock is trading below key moving averages and has seen significant insider selling, indicating caution is warranted.
What is the current technical outlook for IDEXX Laboratories (IDXX)?
The technical outlook for IDEXX Laboratories is bearish, with the stock trading below its 50-day and 200-day moving averages ($546.74 and $592.41) and exhibiting bearish momentum as indicated by its RSI and MACD. Key support levels need to be monitored for potential stabilization.
How does IDEXX Laboratories' valuation compare to its sector peers?
IDEXX Laboratories trades at a premium compared to its Healthcare sector peers. Its P/E ratio of 36.44 and price-to-sales ratio of 9.00 are higher than the sector medians of 31.9 and 3.7, respectively, despite strong profitability metrics.
What are the main risks facing IDEXX Laboratories?
Key risks include substantial insider selling totaling over $75.1 million, a bearish technical trend indicated by price action below key moving averages, and a valuation that is higher than the sector average. These factors suggest potential headwinds for the stock.
What is the consensus rating for IDEXX Laboratories stock?
The consensus rating for IDEXX Laboratories stock is 'Hold', with a consensus score of 59 out of 100. This reflects a balanced view among analysts, with a mix of buy, hold, and some strong buy recommendations.
What is the recent earnings performance of IDEXX Laboratories?
IDEXX Laboratories recently reported a positive earnings surprise for the quarter ending June 2026, beating EPS estimates by 8.65%. This continues a trend of generally positive earnings surprises, although a significant miss occurred in the December 2025 quarter.